ReShape Lifesciences Inc. (RSLS)

ReShape Lifesciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-4.5	-7.13	-11.39	-46.21	-63.15	-21.63
Depreciation & Amortization	0.02	0.02	0.15	2.15	1.97	1.67
Other Amortization	-	-	-	-	0.49	1.7
Loss (Gain) From Sale of Assets	-	-	-0.03	0.53	-	-
Asset Writedown & Restructuring Costs	0.04	0.04	0.78	18.74	30.65	-
Stock-Based Compensation	0.07	0.18	0.77	2.09	12.23	1.32
Provision & Write-off of Bad Debts	0.22	0.11	0.4	-0.04	0.09	0.26
Other Operating Activities	-3.42	-0.04	-3.5	0.13	5.05	8.13
Change in Accounts Receivable	-0.22	0.56	0.13	0.68	-0.28	1.22
Change in Inventory	0.45	0.92	-0.47	-1.19	-0.37	-1.18
Change in Accounts Payable	0.03	0.82	-3.46	0.45	-1.28	-0.99
Change in Other Net Operating Assets	-0.3	0.09	-0.34	0.77	-0.78	0.96
Operating Cash Flow	-7.61	-4.43	-16.96	-21.9	-15.38	-8.55
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Capital Expenditures	-	-	-0.04	-0.13	-0.35	-0.39
Sale of Property, Plant & Equipment	-	-	0.03	0.04	-	-
Cash Acquisitions	-	-	-	-	2.21	-2
Investing Cash Flow	-	-	-0.01	-0.09	1.86	-2.39

Financing Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Long-Term Debt Issued	-	0.65	-	-	1	10.46
Total Debt Issued	0.65	0.65	-	-	1	10.46
Long-Term Debt Repaid	-	-	-	-	-10.5	-
Total Debt Repaid	-0.81	-	-	-	-10.5	-
Net Debt Issued (Repaid)	-0.16	0.65	-	-	-9.5	10.46
Issuance of Common Stock	10.86	0.02	17.57	3.13	46.03	0.68
Other Financing Activities	-	-	-	-	-3.23	-0.06
Financing Cash Flow	10.7	0.68	17.57	3.13	33.3	11.08

Net Cash Flow

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Foreign Exchange Rate Adjustments	-0.02	-0.02	-	0	0.03	-0.11
Net Cash Flow	3.07	-3.77	0.6	-18.86	19.81	0.02

Free Cash Flow

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Free Cash Flow	-7.61	-4.43	-17	-22.03	-15.73	-8.94
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Margin	-117.96%	-55.30%	-195.93%	-196.02%	-115.64%	-79.12%
Free Cash Flow Per Share	-93.58	-214.66	-	-	-	-
Levered Free Cash Flow	-3.67	-1.63	-11.7	-11.71	-3.39	-4.09
Unlevered Free Cash Flow	-3.66	-1.63	-11.7	-11.64	-3.37	-4.51

Additional Metrics

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash Interest Paid	-	-	-	-	0.3	-
Cash Income Tax Paid	0.01	0.01	0.01	0.01	0.1	0.04
Change in Working Capital	-0.04	2.39	-4.13	0.71	-2.71	0.01

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Data Sources Report a data error